Skip to main content
Choose your country to see content specific to that location
Global - English flag
Global - English
  • Global flag
    Global
    • English
  • Czech Republic flag
    Czech Republic
    • Čeština
    • English
  • Germany flag
    Germany
    • Deutsch
    • English
  • Italy flag
    Italy
    • Italiano
    • English
  • Spain flag
    Spain
    • Español
    • English
  • Sweden flag
    Sweden
    • Svenska
    • English
  • United Kingdom flag
    United Kingdom
    • English
  • Science & technology
    Science & technology

    Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.

    • Overview
    • Our pipeline
    • Matrix-M™ adjuvant
    • Recombinant, protein-based nanoparticle vaccine
    • Global vaccine approval/authorization map
    COVID-19 UPDATES

    Novavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.

    Learn more about our COVID-19 updates
  • Who we are
    Who we are

    We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.

    • Our company
    • Our team
    • Our partners
    • Our impact
    Build your future with us

    Join other passionately curious people who are bringing innovative vaccines to the world

    Discover career opportunities
  • Insights
    Insights

    Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

    • Articles
    • Diversity matters: Inclusivity in clinical trials
    • From pandemic to endemic: Why COVID-19 may be here to stay
    • Standing on the shoulders of giants: How a Novavax vaccine is developed
Novavax
  • Medical professionals
  • News & media
  • Investors
  • Careers
Novavax
Global - English flag
Global - English
  • Global flag
    Global
    • English
  • Czech Republic flag
    Czech Republic
    • Čeština
    • English
  • Germany flag
    Germany
    • Deutsch
    • English
  • Italy flag
    Italy
    • Italiano
    • English
  • Spain flag
    Spain
    • Español
    • English
  • Sweden flag
    Sweden
    • Svenska
    • English
  • United Kingdom flag
    United Kingdom
    • English
  • Science & technology
    • Overview
    • Our pipeline
    • Matrix-M™ adjuvant
    • Recombinant, protein-based nanoparticle vaccine
    • Global vaccine approval/authorization map
  • Who we are
    • Our company
    • Our team
    • Our partners
    • Our impact
  • Insights
    • Articles
    • Diversity matters: Inclusivity in clinical trials
    • From pandemic to endemic: Why COVID-19 may be here to stay
    • Standing on the shoulders of giants: How a Novavax vaccine is developed
  • Medical professionals
  • News & media
  • Investors
  • Careers

Sitemap

Home
Science & Technology
Overview
Our pipeline
Matrix-M™ adjuvant
Recombinant protein-based nanoparticle vaccine
Global vaccine authorization / approval map
Who we are
Our company
Executive leadership
Senior management team
Board of directors
Our partners
Insights
Overview
Diversity matters: Inclusivity in clinical trials
Why do we need vaccine booster injections?
From pandemic to endemic: Why COVID-19 may be here to stay
Understanding vaccine safety and efficacy in clinical trials
Standing on the shoulders of giants: How a Novavax vaccine is developed
Creating vaccines to help fight constantly changing threats
Statement on Novavax commitment to equitable access and transparency
Audience centric hub
Medical professionals
News & media
Investors
Careers
Help center
Contact us
Email us
Call us
Legal
Privacy policy
Cookies policy
Terms & conditions
Novavax. Creating tomorrow's vaccines today.

Science & technology

  • Overview
  • Our pipeline
  • Recombinant nanoparticle vaccine technology
  • Matrix-M™ adjuvant technology
  • Global vaccine approval/authorization map

Who we are

  • Our company
  • Executive leadership
  • Senior management team
  • Board of directors
  • Our partners

More information

  • Global authorization site of Novavax COVID-19 Vaccine (recombinant, adjuvanted)
  • Global medical information site
  • Ask medical or scientific questions about our product, report adverse events, and product quality complaints

Contact us

  • Connect with us
  • Sign up for updates
  • Social media guidelines

Careers

41Current opportunities

Novavax is proud to be recognized by the 2021 Top Workplaces USA, reflecting our dedication to an exceptional work culture

Explore current opportunities in:

  • USA flag
    USA
  • CZ flag
    CZ
  • SE flag
    SE
  • EUR flag
    EUR
  • APAC flag
    APAC
TOP WORK PLACES 2021. USA. TOP WORKPLACE FOR 2021 By Energage
© 2023 Novavax. All rights reserved.
  • Privacy policy
  • Cookies policy
  • Terms and conditions
  • Site map
  • Pay Transparency Nondiscrimination Provision
  • Purchase Order Terms and Conditions
You are leaving novavax.com

You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Novavax provides this link as a service to website visitors. Novavax is not responsible for the privacy policy of any third-party websites.

Continue
Cancel
This Novavax website is for medical professionals only.

Click "Continue" only if you are a medical professional.

Continue
Cancel
You are leaving novavax.com

You have selected a link that will take you to a site maintained by a third party. Novavax is not responsible for the Privacy Policy of any third-party websites.

Continue
Cancel
DISCLAIMER:

The information provided on this website is intended for members of the general public in only.

Continue
Cancel